Exciting News from PharmAla Biotech Holdings Inc.

Get Ready for a Game-Changing Development in Biotechnology

Mark your calendars for Dec. 13, 2024

Toronto, Dec. 13, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its intention to complete a non-brokered private placement offering of units of the Company (each, a “Unit”) at a price of $0.18 per Unit for aggregate gross proceeds of $1,400,000 (the “Offering”) or such greater amount at the discretion of the company. The offering may be oversubscribed.

Can you believe it? PharmAla Biotech Holdings Inc. is making waves in the biotechnology industry with their innovative approach to research and development. The announcement of their private placement offering signals a significant step forward in their mission to revolutionize the field with LaNeo™ MDMA and novel derivatives of MDMA.

With a price of $0.18 per Unit, this offering is a prime opportunity for investors to get in on the ground floor of a company that is poised for success. The aggregate gross proceeds of $1,400,000 will fuel PharmAla’s growth and propel them to new heights in the industry. And who knows, the offering may be oversubscribed, opening up even more possibilities for the company’s future.

How This News Will Affect You

As an investor, this announcement could be a game-changer for your portfolio. PharmAla’s focus on innovative biotechnology solutions has the potential to yield significant returns on your investment. By taking advantage of this private placement offering, you could position yourself for financial success in the future.

How This News Will Affect the World

PharmAla’s research and development efforts have the potential to impact the world in a meaningful way. Their work on LaNeo™ MDMA and novel derivatives of MDMA could lead to groundbreaking advancements in healthcare and treatment options. By supporting PharmAla through this private placement offering, you are contributing to the advancement of science and potentially changing the lives of individuals around the globe.

Conclusion

In conclusion, PharmAla Biotech Holdings Inc.’s announcement of a non-brokered private placement offering is a momentous occasion in the world of biotechnology. With a focus on innovation and groundbreaking research, PharmAla is poised for success and poised to make a significant impact on the industry and the world as a whole. Don’t miss out on this exciting opportunity to be a part of something revolutionary.